Pharmacometric dose optimization of buprenorphine in neonatal opioid withdrawal syndrome

Results from Blinded Buprenorphine OR Neonatal morphine solution (BBORN), a previous phase III trial in infants with neonatal opioid withdrawal syndrome (NOWS), demonstrated that sublingual buprenorphine resulted in a shorter duration of treatment and shorter length of hospital stay than the compara...

Descripción completa

Detalles Bibliográficos
Autores principales: Eudy‐Byrne, Rena, Zane, Nicole, Adeniyi‐Jones, Susan C., Gastonguay, Marc R., Ruiz‐Garcia, Ana, Kaushal, Gagan, Kraft, Walter K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604235/
https://www.ncbi.nlm.nih.gov/pubmed/34080312
http://dx.doi.org/10.1111/cts.13074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604235/
https://www.ncbi.nlm.nih.gov/pubmed/34080312
http://dx.doi.org/10.1111/cts.13074

Ejemplares similares